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LETTERS TO THE EDITOR
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nRegarding “Predictors of neck bleeding after eversion
carotid endarterectomy”
We noted with interest the recent study by Baracchini et al,1
which reports a single-center, single-surgeon experience of
eversion carotid endarterectomies (CEA) and factors associated
with increased perioperative bleeding complications, including
re-exploration for bleeding. The study concludes that preopera-
tive treatment with clopidogrel, when used either alone or com-
bined with aspirin was associated with an increased incidence of
bleeding. The authors additionally conclude that aspirin and ticlo-
pidine, when used alone preoperatively were also associated with
an increased incidence of neck hemorrhage following CEA. Re-
view of the study sample, however, reveals that only 110 patients
were taking clopidogrel alone within 1 day of surgery and that only
an additional 10 patients were taking combined therapy (clopi-
dogrel  aspirin). Furthermore, only 95 patients were taking
aspirin alone at the time of CEA, making definitive conclusions
regarding these commonly used antiplatelet agents more difficult.
By comparison, in a recent study by the Vascular Study Group
of New England,2 we evaluated 5264 carotid endarterectomies,
performed by 66 surgeons treated at 15 academic and community
centers. We found that preoperative aspirin (asa; n  3823),
clopidogrel (n  147), or dual antiplatelet therapy (asa  clopid-
ogrel; n  708) use was not associated with any increase in
re-exploration for bleeding after CEA (asa 1.2%, clopidogrel 0.7%,
asa  clopidogrel 1.4%; P  .84).2 Based on this data, we do not
believe that aspirin or clopidogrel increases serious bleeding com-
plications and it remains our practice to routinely perform CEA in
patients taking antiplatelet therapy at the time of surgery, for which
there is sufficient evidence from both randomized controlled trials
and our study group to justify therapy given their impact on
reducing stroke.3-6
The different conclusion reached by Baracchini et al could also
relate to their nonuse of protamine to reverse heparin during CEA,
potentially amplifying bleeding risk if antiplatelet agents are also
being used. Our data has previously shown a significant decrease in
re-exploration for bleeding after CEA (n 4587) when protamine
is used, independent of antiplatelet agents (protamine 0.64% vs no
protamine 1.66%; P  .001).7
Accordingly, we believe that recent studies support the safe
use of both antiplatelet therapy at the time of CEA and the use of
protamine to reverse heparin intraoperatively.
David H. Stone, MD
Philip P. Goodney, MD
Brian Nolan, MD
Section of Vascular Surgery
Dartmouth-Hitchcock Medical Center
Lebanon, NH
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We thank Drs Stone, Goodney, and Nolan for expressing their
nterest in our article and giving us the opportunity to reply to their
etter and further clarify some issues of our study.1
Drs Stone, Goodney, and Nolan believe that the number of
ur patients continuing clopidogrel (n 110) or aspirin (n 95)
r both (n 10) to the day before carotid endarterectomy (CEA)
s too small to draw any definite conclusions about the risk of neck
leeding after CEA. Since our preoperative protocol includes the
iscontinuation of any type of preoperative antiplatelet therapy for
week before surgery, it was already expected that only a small
ercentage of patients would violate this protocol, mainly for their
wn omission. Therefore, the statistical analysis was performed on
his portion of our patient population, and our results show that
reoperative treatment with clopidogrel, when used either alone or
ombined with aspirin, was associated with an increased incidence
f bleeding.
In agreement with Drs Stone, Goodney, and Nolan, we are
uite aware that our results do not represent a universal law and
annot be exported before a large multicenter prospective trial
efinitely clarifies this issue. However, we do believe that our
esults are as significant as those reported in the recently published
tudy by the Vascular Study Group of Northern New England,2 in
hich clopidogrel was not associated with major bleeding compli-
ations. In fact, that observational study has also several limits: (1)
t is not a randomized comparison of patients treated with clopi-
ogrel versus untreated patients; (2) patients’ baseline characteris-
ics before and during CEA are not reported; and (3) the results are
ot controlled for individual surgeon or center effects. Further-
ore, the primary endpoint of that study2 was postoperative
leeding requiring reoperation, while in our investigation, we
ncluded any clinical signs of neck bleeding after CEA, warranting
r not warranting surgical re-exploration. We believe that the
ifferent conclusions reached in the two studies could be related to
hese differences.
With regard to the use of protamine to reverse the effects of
eparin during CEA, we are aware of and we quoted the Stone et
l recently published article showing that protamine reduces bleed-
ng complications without increasing the stroke risk.3 However,
e are still reluctant in applying those results in our everyday
linical practice because of several intrinsic limitations present in
he study by Stone et al,3 mainly due to the nonrandomized
ontrolled nature of the trial and, surprisingly, to the absence of
eurologists involved in the diagnosis of stroke. No information is
iven on how that diagnosis was reached, and certainly cerebral
agnetic resonance was not performed in all patients in order to
